Overview

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Status:
Not yet recruiting
Trial end date:
2027-03-04
Target enrollment:
Participant gender:
Summary
The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals